Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AAA-802 by Novartis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
AAA-802 is under clinical development by Novartis and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...